INCR
Intercure Ltd
NASDAQ · Pharmaceuticals
$0.88
+0.02 (+2.70%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 54.91M | 56.95M | 44.24M |
| Net Income | 8.56M | 10.61M | 8.30M |
| EPS | — | — | — |
| Profit Margin | 15.6% | 18.6% | 18.8% |
| Rev Growth | +12.7% | -4.9% | +12.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 21.10M | 21.12M | 16.64M |
| Total Equity | 99.39M | 85.08M | 101.00M |
| D/E Ratio | 0.21 | 0.25 | 0.16 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 18.71M | 17.54M | 14.43M |
| Free Cash Flow | 13.25M | 14.62M | 7.88M |